Teva Reports 1Q Results Above Our Expectations, but Challenges Remain
We may moderately increase our fair value estimate for Teva as Copaxone and Austedo sales along with cost-saving efforts may keep performance running slightly ahead of our expectations. Other positive news includes management’s estimation it can still launch chronic migraine drug fremanezumab by year-end following potential near-term resolution of regulatory issues at API manufacturer Celltrion. Despite some of this quarter’s decent performance and management raising its year-end outlook, we sti...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.